Skip to content
DraconiticResearch
Search Sources API
220,782 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BYFrontiers in medicine

Case Report: Successful peripartum management of acquired hemophilia A relapse during pregnancy.

  • Hongyun Chen1
  • Xiaochen Yu2
  • Tienan Zhu1
  1. 1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  2. 2Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Read full textPDFDOICite

Abstract

Background

Few reports of Pregnancy-related Acquired hemophilia A (AHA) manifested prenatally. Due to rarity, there are no definitive guidelines for the peripartum management of pregnant women with AHA and their newborns.Case presentation

we report a 30-year-old woman with relapsed AHA during pregnancy. She maintained partial remission with cyclosporin, underwent cesarean section with rFVIIa prophylaxis, and controlled postpartum bleeding. The newborn had transient FVIII inhibitors without bleeding.Conclusion

Bypassing agents effectively prevent postpartum hemorrhage in AHA. Close monitoring is necessary for newborns. We observed that immunosuppressive therapy administered during pregnancy and the postpartum period failed to eliminate FVIII inhibitors, highlighting contraception necessity for non-remission patients.

Related

  1. Successful management of high-risk proliferative diabetic retinopathy during pregnancy with intravitreal faricimab
    Oxford medical case reportsPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. PO123 | PERIOPERATIVE MANAGEMENT OF FEMORAL FRACTURE SURGERY IN AN ELDERLY PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB
    Chiara Simion
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  3. PO131 | BEYOND THE INHIBITOR TITER: THE IMPORTANCE OF EARLY COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
    Myriam Luongo
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  4. PO161 | A REGIONAL DIGITAL NETWORK FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A: A MODEL FOR INTEGRATED CARE
    Marta Mattana
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  5. PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS
    Antonio Coppola
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ

Cite

BibTeXRIS
BibTeX
@article{chen2026case,
  title = {{Case Report: Successful peripartum management of acquired hemophilia A relapse during pregnancy.}},
  author = {Hongyun Chen and Xiaochen Yu and Tienan Zhu},
  journal = {Frontiers in medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fmed.2026.1963805},
  url = {https://europepmc.org/article/MED/43010925},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Case Report: Successful peripartum management of acquired hemophilia A relapse during pregnancy.
AU  - Hongyun Chen
AU  - Xiaochen Yu
AU  - Tienan Zhu
PY  - 2026
DA  - 2026/10/27
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2026.1963805
UR  - https://europepmc.org/article/MED/43010925
AB  - Background  Few reports of Pregnancy-related Acquired hemophilia A (AHA) manifested prenatally. Due to rarity, there are no definitive guidelines for the peripartum management of pregnant women with AHA and their newborns.Case presentation  we report a 30-year-old woman with relapsed AHA during pregnancy. She maintained partial remission with cyclosporin, underwent cesarean section with rFVIIa prophylaxis, and controlled postpartum bleeding. The newborn had transient FVIII inhibitors without bleeding.Conclusion  Bypassing agents effectively prevent postpartum hemorrhage in AHA. Close monitoring is necessary for newborns. We observed that immunosuppressive therapy administered during pregnancy and the postpartum period failed to eliminate FVIII inhibitors, highlighting contraception necessity for non-remission patients.
SN  - 2296-858X
ER  -